Veracyte
GenomeWeb Top 40 Drops 3 Percent in 2024, Reflecting Larger Life Science Struggles in Stock Market
The Dow Jones Industrial Average rose 13 percent year over year, and the Nasdaq rose 29 percent, but the Nasdaq Biotech Index declined 1 percent.
Updated NCCN Guidelines Adjust Ratings for Prostate Cancer Genetic Tests
The newest version ups its endorsement of somatic genomic testing to "recommended" for advanced cancers and shifts its recommendations on early-stage risk assays.
Wolfe Research Initiates Coverage of Grail With Peer Perform, Veracyte With Outperform Rating
Grail's flagship product, Galleri, detects more than 50 types of cancer, while Veracyte offers tests intended to personalize treatment for thyroid, breast, and lung cancer.
As the company explores new testing areas and technologies, the prostate cancer prognostic has become an important backbone.
UBS Initiates Coverage of Veracyte With Buy Rating
Analysts noted that they envision "durable growth" in Veracyte's Afirma and Decipher Prostate tests and "long-term growth potential" from its MRD testing business.